RxDoctor Payments DataLook up a doctor →

Kelly Dugan, NP

Nurse Practitioner · Chicago, ILNPI 1528580065

Payments from drug & device makers

$14,644in general payments, 2019–2025

Across 619 payments — averaging $23.66 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sumitomo Pharma America, Inc.$2K
  • Astellas Pharma US Inc$1K
  • Johnson & Johnson$1K
  • Coloplast$1K
  • Teleflex LLC$869
  • Bayer$746
  • plus $8K from 38 others

What the payments were for

  • Speaking & faculty fees$3602%
  • Travel & lodging$8156%
  • Food & beverage$12,80887%
  • Education$6615%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$14,644 in reported general payments places this provider in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

See all nurse practitioner providers in Illinois

Medicare billing

Part B allowed, 2024
$45,403
Medicare patients
220
Services billed
1,825

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OrgovyxRelugolix36$93,369
GemtesaVibegron53$55,860
MyrbetriqMirabegron48$38,191
Abiraterone Acetate14$32,148
Tamsulosin Hcl341$8,017
Solifenacin Succinate108$6,898
Bethanechol Chloride79$5,271
Finasteride160$2,060
Alfuzosin Hcl ErAlfuzosin Hcl86$1,784
Silodosin29$1,644
Testosterone15$1,643
Estradiol15$846
Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip36$844
Oxybutynin Chloride27$815
Doxazosin Mesylate49$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Orgovyx, Gemtesa$1,753$149,23089 claims
Astellas Pharma US IncMyrbetriq$1,301$38,19148 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,869 nurse practitioner providers in Illinois.

Other nurse practitioner in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →